Sameer K. Deshpande, BS; Raiden B. Hasegawa, BA; Amanda R. Rabinowitz, PhD; et al.
free access
JAMA Neurol. 2017;74(8):909-918. doi:10.1001/jamaneurol.2017.1317
This cohort study uses data from the Wisconsin Longitudinal Study to estimate the association of playing high school football in the 1950s with cognitive impairment and depression at 65 years of age.
Michel Berg, MD; Timothy E. Welty, PharmD; Barry E. Gidal, PharmD; et al.
free access
JAMA Neurol. 2017;74(8):919-926. doi:10.1001/jamaneurol.2017.0497
This randomized clinical trial examines whether a branded and a generic antiepileptic drug are biologically equivalent when administered to adults with epilepsy who are taking concomitant antiepileptic drugs.
Neal S. Parikh, MD; Babak B. Navi, MD, MS; Yecheskel Schneider, MD; et al.
free access
has audio
JAMA Neurol. 2017;74(8):927-932. doi:10.1001/jamaneurol.2017.0923
This cohort study of Medicare claims data investigates the association between cirrhosis and various stroke types.
-
Podcast:
Cirrhosis and Stroke in a Nationally Representative Cohort (JAMA Neurology)
-
Podcast:
Cirrhosis and Stroke in a Nationally Representative Cohort
Danna Jennings, MD; Andrew Siderowf, MD; Matthew Stern, MD; et al.
free access
JAMA Neurol. 2017;74(8):933-940. doi:10.1001/jamaneurol.2017.0985
This longitudinal observational study determines if the combination of smell identification testing followed by dopamine transporter imaging can accurately and efficiently identify individuals from the general population at risk for conversion to a clinical diagnosis of Parkinson disease.
Clinical Trial
Rajesh Pahwa, MD; Caroline M. Tanner, MD, PhD; Robert A. Hauser, MD, MBA; et al.
open access
JAMA Neurol. 2017;74(8):941-949. doi:10.1001/jamaneurol.2017.0943
This randomized, double-blind, placebo-controlled clinical trial evaluates the efficacy and safety of extended-release ADS-5102 (amantadine) 274-mg capsules for treatment of levodopa-induced dyskinesia in patients with Parkinson disease.
Andrea Morotti, MD; H. Bart Brouwers, MD, PhD; Javier M. Romero, MD; et al.
free access
JAMA Neurol. 2017;74(8):950-960. doi:10.1001/jamaneurol.2017.1014
This secondary analysis of a randomized clinical trial investigates whether the spot sign is associated with intracerebral hemorrhage expansion and whether intensive blood pressure reduction reduces hematoma expansion and improves outcomes.
David Baker, PhD; Samuel S. Herrod, BSc; Cesar Alvarez-Gonzalez, PhD; et al.
free access
JAMA Neurol. 2017;74(8):961-969. doi:10.1001/jamaneurol.2017.0676
This analysis of unpublished data from pivotal phase 3 trials of alemtuzumab in the treatment of multiple sclerosis investigates the association of efficacy with long-term depletion of memory T and B cells and hyperrepopulation of immature B cells.
Eduardo De Pablo-Fernandez, MD; Carmen Tur, MD, MSc, PhD; Tamas Revesz, MD, PhD; et al.
free access
JAMA Neurol. 2017;74(8):970-976. doi:10.1001/jamaneurol.2017.1125
This study examines the association of time of onset of autonomic dysfunction with disease progression and survival in Parkinson disease.
Samuel Frank, MD; David Stamler, MD; Elise Kayson, MS, RNC, ANP; et al.
free access
JAMA Neurol. 2017;74(8):977-982. doi:10.1001/jamaneurol.2017.1352
This open-label, single-arm study evaluates the safety and explores the efficacy of conversion from tetrabenazine to deutetrabenazine in patients with chorea associated with Huntington disease.
Neda Razaz, PhD; Torbjörn Tomson, MD; Anna-Karin Wikström, MD, PhD; et al.
free access
JAMA Neurol. 2017;74(8):983-991. doi:10.1001/jamaneurol.2017.1310
This population-based cohort study examines the outcomes of epilepsy and use of antiepileptic drugs during pregnancy in women and infants.
Eri Noguchi, MD; Akinori Uruha, MD, PhD; Shigeaki Suzuki, MD, PhD; et al.
free access
JAMA Neurol. 2017;74(8):992-999. doi:10.1001/jamaneurol.2017.0934
This cohort study aims to elucidate the clinical features of myositis in patients with antisynthetase syndrome.